OncoMatch/Clinical Trials/NCT06249191
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Is NCT06249191 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for diffuse large b-cell lymphoma.
Treatment: Cyclophosphamide · Doxorubicin · Etoposide · Mosunetuzumab · Prednisone · Vincristine — This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as etoposide, doxorubicin, vincristine, cyclophosphamide and prednisone work in different ways to stop the growth of cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mosunetuzumab with chemotherapy may be safe, tolerable and/or effective in treating patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MYC rearrangement
Allowed: BCL2 rearrangement
Allowed: BCL6 rearrangement
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy for DLBCL
Exception: Prednisone ≤ 100 mg for up to 10 days within 28 days prior to starting study treatment (must be discontinued by treatment start); one cycle of RCHOP or DA R EPOCH
Prior treatment for DLBCL. Exceptions: Prednisone of ≤ 100 mg for up to 10 days, within 28 days prior to starting study treatment. Prednisone or equivalent corticosteroid must be discontinued by the time of treatment start; One cycle of RCHOP or DA R EPOCH
Lab requirements
Blood counts
ANC ≥ 1.0 ×10^9/L (unless due to underlying disease); Platelet count ≥ 75 ×10^9/L (unless due to underlying disease); Hemoglobin ≥ 10 g/dL (unless due to underlying disease)
Kidney function
Serum creatinine ≤ ULN; or estimated creatinine clearance ≥ 50 mL/min by Cockcroft Gault method or other institutional standard methods
Liver function
AST or ALT ≤ 2.5 x ULN within 14 days of initiation of study treatment; total bilirubin < 1.5 x ULN within 14 days of initiation of study treatment
Cardiac function
Left ventricular ejection fraction (LVEF) within institutional limits of normal by MUGA or ECHO
ANC ≥ 1.0 ×10^9/L (14 days prior to first mosunetuzumab dose) (unless inadequate function is due to underlying disease...); Platelet count ≥ 75 ×10^9/L (14 days prior...); Total hemoglobin ≥ 10 g/dL (21 days prior...); Serum creatinine ≤ ULN; or estimated creatinine clearance ≥ 50 mL/min...; LVEF defined by MUGA or ECHO within institutional limits of normal; AST or ALT ≤ 2.5 x ULN within 14 days...; total bilirubin < 1.5 x ULN within 14 days...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OHSU Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify